MARKET

KTRA

KTRA

Kintara Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.500
+0.110
+7.91%
After Hours: 1.450 -0.05 -3.33% 17:44 01/15 EST
OPEN
1.380
PREV CLOSE
1.390
HIGH
1.590
LOW
1.380
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
0.3800
MARKET CAP
36.99M
P/E (TTM)
-0.7551
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kintara initiates recruitment for VAL-083's study arm in the GBM AGILE trial
Kintara Therapeutics (KTRA) has announced that patient recruitment in the Global Coalition for Adaptive Research (GCAR) Phase 2/3 trial for glioblastoma ((GBM)), has commenced.The company is targeting 150-200 patients with
Seekingalpha · 4d ago
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial
, /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that patient recruitment has commenced in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma (GBM).  The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a revolutionary, patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. 
PR Newswire - PRF · 4d ago
Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that patient recruitment has commenced in the Global Coalition for Adaptive ...
PR Newswire · 4d ago
Kazia, Kintara’s gliblastoma candidates to be evaluated GBM AGILE study
The Global Coalition for Adaptive Research ((GCAR)) in collaboration with Kazia ([[KZIA]] -3.4%) and Kintara ([[KTRA]] -1.3%), have announced the activation of Kazia's paxalisib and Kintara's VAL-083 in Glioblastoma trial
Seekingalpha · 01/06 20:09
Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazias Paxalisib and Kintaras VAL-083 in GBM AGILE Trial
GCAR, Kazia, and Kintara Announce Commencement of Kazia’s paxalisib and Kintara’s VAL-083 in GBM AGILE
Business Wire · 01/06 18:00
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
, /PRNewswire/ --  (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its President and CEO will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place .
PR Newswire - PRF · 01/05 13:00
Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its President and CEO Saiid Zarrabian will present at the H.C. Wainwright Bi...
PR Newswire · 01/05 13:00
Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit
, /PRNewswire/ --  (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it will be presenting at the 2 Annual Glioblastoma Drug Development Virtual Summit on Thursday, December 10, 2020 at .
PR Newswire - PRF · 12/03/2020 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KTRA. Analyze the recent business situations of Kintara Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KTRA stock price target is 4.250 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 22
Institutional Holdings: 304.96K
% Owned: 1.24%
Shares Outstanding: 24.66M
TypeInstitutionsShares
Increased
1
80.78K
New
13
-31.65K
Decreased
1
2.86K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Independent Director
Robert Hoffman
President/Chief Executive Officer/Director
Saiid Zarrabian
Chief Financial Officer
Scott Praill
Chief Scientific Officer
Dennis Brown
Director
John Liatos
Director
Keith Murphy
Independent Director
Robert Toth
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KTRA
Kintara Therapeutics Inc, formerly DelMar Pharmaceuticals, Inc., is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kintara Therapeutics Inc stock information, including NASDAQ:KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.